Abstract 1220: Association Between KRAS/STK11/KEAP1 Mutations & Outcomes in POSEIDON: Durva ± Tr...

Abstract 1220: Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC (POSEIDON cohort was reported in a recent WCLC)—Dr. Solange Peters